Abstract

RUBIO-MANZANARES-DORADO, Mercedes et al. Post-transplant lymphoproliferative disease in liver transplant recipients. Rev. esp. enferm. dig. [online]. 2017, vol.109, n.6, pp.406-413. ISSN 1130-0108.  https://dx.doi.org/10.17235/reed.2017.4228/2016.

Introduction: Post-transplant lymphoproliferative syndrome (PTLD) is a rare and potentially life-threatening complication after liver transplantation. The aim of this study was to analyze the clinicopathologic features related to PTLD in a single institution after liver transplantation. Methods: Observational study where we have retrospectively analyzed 851 cases who underwent liver transplantation. Ten cases have developed PTLD. Their clinical-pathological characteristics and the treatment received have been analyzed. Results: PTLD incidence was 1.2% (10/851). The mean time from liver transplantation to PTLD diagnosis was 36 months (range 1.2 to 144 months). PTLD localization was extranodal in all cases, the most frequent location being intestinal. Seven cases showed a monomorphic lymphoma which in all cases was differentiated B cell lymphomas. Fifty per cent of the series were seropositive for Epstein-Barr virus. Five patients were alive at the time of the review. Among these patients, we observed three cases of complete remission and two cases of disease stabilization. The death rate was higher in the first year after diagnosis of PTLD. Conclusion: PTLD is a rare complication after liver transplantation, but it may pose a threat to the life of a liver transplant recipient. It is essential to identify patients at risk, to establish an early diagnosis and treatment that can change the outcome of the disease.

Keywords : Post-transplant lymphoproliferative disease; Liver transplantation; Rituximab.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )